Clinical trials: Clozapine Resistant Schizophrenia
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Schizophrenia, Insulin Resistance
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.
- Trial name
- NCT00345033
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
We propose an eight-week, double-blind, placebo-controlled trial of rosiglitazone in schizophrenia subjects treated with clozapine using Bergman's Minimal Model (MINMOD) intravenous glucose tolerance test.
- Trial name
- NCT00337350
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association